Nanyang Biologics' AI Leap: Drug Discovery Revolution with Equinix & HPE - Life AI Weekly #32

Hi there,

Welcome to this week's edition of Life AI Weekly, where we delve into the latest advancements in Healthcare and Life Sciences AI. This week, we explore a range of exciting developments, including Nanyang Biologics partnering with Equinix and HPE to enhance AI-driven drug discovery, and Veeva Systems collaborating with Amgen to streamline clinical trials. Additionally, Raina Biosciences has launched the GEMORNA AI Platform, aiming to revolutionize the field of genomics.

In other news, the University of Pennsylvania is leveraging AI to aid in antibiotic discovery, while Bioneex AI is making strides in biotech drug discovery. Furthermore, Norma has achieved a remarkable 73x speed increase in drug development using NVIDIA CUDA-Q. Stay tuned as we continue to bring you the latest insights and breakthroughs in the intersection of AI and healthcare.

Assort Health has raised $50 million in a Series B funding round to enhance its AI-driven patient communication services, aiming to automate tasks like scheduling in specialty healthcare practices. Meanwhile, Argent BioPharma Ltd. announced its acquisition of key assets from AusCann Group Holdings Ltd. for $15 million, including the Neuvis® drug delivery platform and pre-clinical data for epilepsy.

Nanyang Biologics has partnered with Equinix and HPE to create Vecura, an AI-driven drug discovery platform, establishing the largest natural drug compound library in Singapore. Meanwhile, Veeva Systems and Amgen have announced a collaboration to enhance clinical trial innovation using the Veeva Clinical Platform, aiming to streamline operations and accelerate new medicine development.

SmartLabs and Sonrai Analytics have announced a strategic partnership to integrate AI data management into research centers, enhancing capabilities for member companies. Meanwhile, the University of Oxford and the Ellison Institute of Technology have launched a £118m AI-driven vaccine research program focusing on antibiotic resistance and immune response.

Ben Lamm and Harvard researcher George Church have launched Astromech, an AI company that has raised $30 million, focusing on AI and biotechnology.
Corsera Health, founded by biotech veterans John Maraganore and Clive Meanwell, aims to tackle cardiovascular disease with an AI tool and an RNAi drug to predict and target heart disease risk factors.

OpenAI has appointed Nate Gross and Ashley Alexander to lead its healthcare initiatives, signaling a strategic shift in the sector. Meanwhile, Canarys has launched Auryis, an AI-driven compliance platform for the Pharma and Life Sciences industries, offering real-time insights to manage non-compliance risks.